Distinct acute lymphoblastic leukemia (ALL)-associated Janus Kinase 3 (JAK3) mutants exhibit different cytokine-receptor requirements and JAK inhibitor specificities

Elisabeth Losdyck, Tekla Hornakova, Lorraine Springuel, Sandrine Degryse, Olga Gielen, Jan Cools, Stefan N. Constantinescu, Elisabetta Flex, Marco Tartaglia, Jean Christophe Renauld, Laurent Knoops

Research output: Contribution to journalArticlepeer-review

Abstract

Background: JAK3, a tyrosine kinase associated to cytokine receptors, is frequently mutated in leukemia. Results: JAK3L857P induces constitutive signaling independently of cytokine receptors and JAK1, in contrast to other JAK mutants. Conclusion: Different JAK mutants signal through distinct mechanisms and show different sensitivity to JAK1- or JAK3- specific inhibitors. Significance: Depending on the JAK residue mutated, patients will require different treatments.

Original languageEnglish
Pages (from-to)29022-29034
Number of pages13
JournalJournal of Biological Chemistry
Volume290
Issue number48
DOIs
Publication statusPublished - Nov 27 2015

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Fingerprint Dive into the research topics of 'Distinct acute lymphoblastic leukemia (ALL)-associated Janus Kinase 3 (JAK3) mutants exhibit different cytokine-receptor requirements and JAK inhibitor specificities'. Together they form a unique fingerprint.

Cite this